Key Insights Significantly high institutional ownership implies Aquestive Therapeutics' stock price is sensitive ...

In a challenging market environment, Centrexion Therapeutics Corp stock has touched a 52-week low, with shares falling to $0.9. According to InvestingPro data, the stock shows significant volatility ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...

January 23, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, all ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.

ProQR Therapeutics (PRQR ... dynamics amid a flurry of earnings reports and economic data releases. In this context, penny stocks—often associated with smaller or newer companies—continue ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...